• Skip to main content
  • Skip to footer

bioSyntagma

Eliminating trial-and-error cancer treatments

  • Technology
  • Company
  • News
  • Contact

Jun 08 2021

bioSyntagma Launches First Multi-Omic Spatial Platform for Clinical Applications

bioSyntagma®, Inc unveiled the world’s first high-plex multi-omic spatial workflow designed for clinical samples and diagnostic applications.  Compatible with FFPE and large resections up to an inch in size, the Molecular Fingerprint™ (mPrint) technology has been demonstrated to map tumor microenvironments with custom PCR panels, targeted and total sequencing, and spatial imaging at resolutions ranging from single-cell to complex regions of interest.  bioSyntagma’s solution is the first to provide a pathway to diagnostic applications with its proprietary spatial-diagnostic machine learning engine that classifies tissues based on tumor microenvironment.  

Read more here:
https://www.prnewswire.com/news-releases/biosyntagma-launches-first-multi-omic-spatial-platform-for-clinical-applications-301306965.html

Written by bioSyntagma · Categorized: Featured

Footer

Home Technology Company News Contact


2113 S 48th St. Ste 103, Tempe, AZ 85282
info@biosyntagma.com
© 2021 bioSyntagma. All Rights Reserved.